OxAG3 – novel antibiotic candidate to treat life threatening Gram-neg. infections

OxAG3 is a novel first-in-class candidate that was designed using the OxAG logi-biotic platform, and which targets MDR Gram negative bacteria like the ESKAPE pathogens Pseudomonas, Klebsiella, Acinetobacter and Enterobacter. The compound was designed using natural products as a basis and combining active core elements with the necessary compound features. OxAG now runs a med-chem driven development program to fine tune the structure and improve bioavailability.